Working Groups

Latest News

NEW! ISAC Fellow Award!

Recipients of ISAC Fellow Award announced!

Read More
ISAC 2019 Award Winners!

The 2019 ISAC Awards were announced during the 31st ICC - 4th GCCMID.

Read More

Membership

Current Officers

F Amer

Chair

Fatma Amer

Vice-Chair

Jurgen Rockstroh

Secretary

Khan F. Mohammad Ayaz

Treasurer

Ergenekon Karagoz

All Members

Mamun Al-Mahtab (Bangladesh)
Joop Arends (The Netherlands)
Shafiqul Bari (Bangladesh)
Junaid Bhai (Bangladesh)
Rehab Elsaid (Egypt)
Hakan Erdem (Turkey)
N. Furusyo (Japan)
Noha Hammad (Egypt)
D. Januszkiewicz-Lewandowska (Poland)
Lanjuan Li (China)
T. Lizuka (Japan)
Aouni Mahjoub (Tunisia)
Mojca Matičič (Slovenia)
Syed Ghulam Mogni Mowla (Bangladesh)
Monkez Moteia (Egypt)
Ghada Nasr (Egypt)
N. Nazia (Bangladesh)
Kemal Ozden (Turkey)
Fazle Rabbi Chowdhury (Bangladesh)
W. F. Tang (China)
Adnan Toumi (Tunisia)
P. Zhao (China)




How to Join

Members of an ISAC Member Society are eligible to join any of our Working Groups. If you are a member and would like to join this group, please contact the Chairperson and Secretary (if applicable).

Aims and Objectives

Viral infections are spread worldwide and result in significant morbidity and mortality. Globally, viral hepatitis is of particular concern as it was the seventh leading cause of death in 2013, up from the 10th leading cause in 1990. The most important hepatitis viruses are hepatitis B and C. About 2 billion people in the world have evidence of past or current HBV infection, with 240 million chronic carriers of HBsAg. HBV leads to 650,000 deaths annually as a result of viral hepatitis–induced liver disease. An estimated 71 million people are chronically infected with HCV worldwide. About 55-85% of these people infected progress to chronic HCV infection, with a 15-30% risk of developing liver cirrhosis within two decades. Approximately 399,000 people die each year from hepatitis C, mostly from cirrhosis and hepatocellular carcinoma. Antiviral medicines can cure more than 95% of persons with hepatitis C infection, thereby reducing the risk of death from liver cancer and cirrhosis, but access to diagnosis and treatment is low. Hepatitis can also result from infection by other A- E hepatitis and fourteen other families of viruses.


Aim of the Viral Infection Working Group

To work together at an international level, in multiple areas related to viral infections with regards to education and research activities. Participation of junior colleagues in all activities is strongly encouraged.

 

Objectives

1. To hold “Viral/Hepatitis Symposiums” in all future meetings whether national, regional or international.
2. To carry out relevant research activities. 
3. To carry out a series of “post graduate courses in viral infections”.
4. To link and synergize with other medical societies and stakeholders working around viral infections

Presentations / Symposia

7 - 9 November 2019

Symposium on viral infections within the 17th European AIDS Conference in Basel, Switzerland

November 2019

Hepatitis Symposium”, 31st ICC- 4th GCCMID, November2019 – Dubai, UAE.

October 2019

“Hepatitis Symposium”, 10th SEEC, Budva, Montenegro.

March 2019

International Forum on Infectious Diseases (IFID) - Istanbul, Turkey.

Hepatitis Symposium 

23-24 Nov 2018

2nd International Conference on Gastroenterology and Hepatology - Bangkok, Thailand.

Surveillance and impact of occult hepatitis B virus, SEN virus and TT virus among hemodialysis patients with chronic hepatitis C virus infection in the Eastern Province of Egypt

April 2017

27th ECCMID - Vienna, Austria.

Large-scale hepatitis C combating campaigns in Egypt and Georgia - past, current and future challenges

 The Revolution of Treatment of hepatitis C virus by direct acting antivirals; has the story come to the end?

  • 14th National Hepatogastroenterology Congress- 5th National Gastroenterology Surgery Congress- 1st European Gastroenterological Association Symposium. 5-8 April 2017, Antalya, Turkey.
  • 17th International Conference and Scientific Seminar of Bangladesh Society of Medicine. December 2016, Dhaka, Bangladesh. 
  • Hepatitis 2016, 3rd World Congress on Hepatitis and Liver Diseases. 10-12 October 2016, Dubai, UAE.
  • 7th Conference South East European Conference on Chemotherapy and Infection (SEEC ) & the Romanian National Congress of Anti-infectious Chemotherapy. 13-15 October 2016, Sibiu, Romania.
 March 2016

17th International Congress on Infectious Diseases (ICID) - Hyderabad, India.

Egyptian experience in the management of HCV infection 

Nov 2015

6th SECC - Thessaloniki, Greece

Hepatitis Symposium

July 2015

World Congress on Hepatitis - Orlando, Florida.

Burden of HCV disease in Egypt and efforts to combat

Dec 2014

3rd National Conference on Tropical Medicine & Toxicology -Sylhet, Bangladesh

In the era of direct acting antivirals; is there a need for an HCV vaccine?

Epidemiology of hepatitis C virus infection in Egypt; overt and occult

• 5th International Conference of SPIC-EGYPT, 6th International Infection Control Conference of TBRI. November 2014, Cairo, Egypt.
• 5th SEEC. October 2014, Bled, Slovenia.

April 2014

3rd conference of FASCMID & 10th Conference of ArAPUA - Dead Sea, Jordan.

Direct- acting antivirals; a new horizon in the treatment of hepatitis C virus infections

Publications

Surveillance and impact of occult hepatitis B virus, SEN virus and TT virus among hemodialysis patients with chronic hepatitis C virus infection in the Eastern Province of Egypt”. Submitted for publication
HCV infection among asymptomatic Egyptian children. In final stage of writing

Epidemiology of Hepatitis C Virus Infection in Egypt

Amer FA, Gohar M and Yousef M. International Journal of Tropical Disease & Health. 2015: 7(3): 119-131.

Immunological mechanisms controlling hepatitis C virus infection.

Amer FA. Asian Pacific Journal of Tropical Disease. 2015: 5(2): 85-90

Immune-based strategies for treatment and prevention of hepatitis C virus infection.

Amer FA, Mansour MA, Mansour SA. The International Arabic Journal of Antimicrobial Agents. 2014: 1

Multicenter Study

Developing a multicenter study “Real world experience of interferon-based, versus interferon-free therapy of chronic hepatitis C in different ethnic populations” and recruiting participants.

Future / Ongoing Activities

• Continue with HCV multicenter study.

• Working on the possibility of carrying out:
a. Another multicenter study
b. Postgraduate courses

Last updated: December 11th-2019